Why the TACTI-004 Phase III outcome challenges assumptions about LAG-3 immune activation
Immutep Limited halts its TACTI-004 lung cancer trial after a futility analysis. Discover what the setback means for eftilagimod alfa and LAG-3 immunotherapy.
Firefly Neuroscience explores AI analysis of brain waves for ADHD subtype detection
Firefly Neuroscience explores EEG brain wave biomarkers for ADHD subtype detection using AI. Discover how neurodiagnostics may reshape ADHD diagnosis.
BridgeBio Pharma advances BBP-418 toward FDA filing after Phase 3 muscular dystrophy trial data
BridgeBio Pharma reports Phase 3 BBP-418 results and prepares FDA filing. Could this become the first therapy for limb-girdle muscular dystrophy?
Could Io Therapeutics’ IRX4204 reshape the science of breast cancer prevention?
Could IRX4204 help prevent triple-negative breast cancer? Discover what new RXR agonist research could mean for the future of breast cancer prevention.
What PolTREG-T1D reveals about the future of cell therapy in autoimmune diseases
PolTREG advances its TREG cell therapy for type 1 diabetes toward EU approval. Learn what this milestone means for autoimmune disease treatment.
What Toro Neurovascular’s FDA-cleared Toro 88 catheter means for the neurovascular device market
FDA clears Toro Neurovascular’s Toro 88 catheter for stroke intervention. Discover how this device could reshape neurovascular access and aspiration thrombectomy.
Oragenics launches Phase IIa trial of ONP-002 as drug developers revisit traumatic brain injury therapies
Oragenics begins Phase IIa testing of ONP-002 for concussion. Discover how this trial could reshape drug development for traumatic brain injury.
What QT Imaging’s latest FDA clearance reveals about the future of radiation-free breast imaging
QT Imaging wins FDA clearance for an upgraded Breast Acoustic CT scanner. Discover what this means for radiation-free breast imaging.
Connect Biopharma advances rademikibart data as global competition grows in eczema biologics
Rademikibart Phase 3 eczema data will debut at AAD 2026. Discover what the trial could mean for IL-4 receptor biologics and global dermatology drug competition.
How Citius Oncology’s LYMPHIR program reflects a broader shift in immuno-oncology strategy
Citius Oncology reports early LYMPHIR plus pembrolizumab data in gynecologic cancers. Explore what the study reveals about the future of immuno-oncology strategies.